In an AML comparator study reporting Adooq-sourced crenolanib, cellular IC50 values were 3.1 ± 0.06 nM in MV4-11 and 4.5 ± 0.8 nM in MOLM-14, versus 6.6 ± 0.03 nM and 15.6 ± 0.4 nM in MOLM-14 carrying additional D835Y and F691L mutations, respectively (mean ± SD). Methods specify a 72 h exposure followed by CellTitre-Blue, although Results call the assay MTT; the values are retained as the reported viability/antiproliferative endpoints. Supplier attribution does not establish a catalog number, salt or current lot. [3]
A separate study found approximately 10 nM cellular IC50 activity in FLT3-ITD AML lines Molm14 and MV4;11 after 48 h. KIT-driven HMC 1.1 and HMC 1.2 cells were much less responsive at 100 nM. This comparison supports model-dependent cellular selectivity; loss of viability at higher concentrations prevents an absolute KIT-sparing interpretation. [4]
Crenolanib comparator activity in AML cell lines
Cell-based study · MV4-11, MOLM-14, MOLM-14 (FLT3-ITD, D835Y), and MOLM-14 (FLT3-ITD, F691L) [3]
The reported crenolanib IC50 values were higher in the two secondary-mutant MOLM-14 models than in parental MOLM-14. These are antiproliferative/viability assay endpoints, not administered concentrations.
Literature-Reported Treatment Conditions
- Treatment concentration
- Serially diluted compound; highest tested concentration 10 μM (assay method).
- Exposure duration
- 72 h exposure, followed by 4 h after addition of viability reagent.
- Method
- CellTitre-Blue fluorescence per section 2.2; do not relabel as a direct cell count or apoptosis assay.
- Vehicle
- DMSO stock and DMSO-normalized control; final DMSO percentage not reported in section 2.2.
- Co-treatment
- Crenolanib alone; other inhibitors were separate comparators.
- Reported limits
- Exact salt, catalog number and lot absent from the selected material description. Figure 4 reports triplicates; independence of those replicates is not specified. Results call the assay MTT, whereas section 2.2 specifies CellTitre-Blue.
Methods and source locations
Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib
Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.
Table 1, crenolanib row and header; sections 2.1, 2.2 and 3; Figures 2 and 4
MV4-11 antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption
MOLM-14 antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption
MOLM-14 (ITD, D835Y) antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption
MOLM-14 (ITD, F691L) antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption
FLT3 binding and evidence consistent with type I inhibition
Biochemical assay · Purified FLT3 variants; phosphorylated and nonphosphorylated WT Abl and Abl Q252H [1]
Crenolanib bound FLT3 variants with different affinities. Preferential binding to active Abl was used as indirect evidence for type I properties; it is not a direct FLT3 co-crystal measurement.
Literature-Reported Treatment Conditions
- Method
- In vitro kinase binding; Kd values are endpoints, not treatment doses.
- Vehicle
- DMSO formulation reported for in vitro assays.
- Co-treatment
- Single-agent binding experiments.
- Reported limits
- Binding titration concentrations, exposure time and replicate details not retrieved from the supplement; not supplied by inference.
Methods and source locations
Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib
Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.
Table 1; Methods: Binding affinity for FLT3 and Abl variants; Results: Crenolanib is a FLT3 inhibitor with type I properties
WT FLT3 binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes
FLT3-ITD binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes
FLT3-ITD/D835V binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes
FLT3-ITD/F691L binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes
Active versus inactive WT Abl binding: KdELECT; phosphorylated active versus nonphosphorylated inactive Abl. — Table 1, Abl variant rows; Results: type I properties
Active versus inactive Abl Q252H binding: KdELECT; active versus inactive Abl Q252H. — Table 1, Abl variant rows; Results: type I properties
Differential viability response in FLT3-ITD and KIT-driven cells
Cell-based study · Molm14 and MV4;11 FLT3-ITD AML lines; HMC 1.1 (KIT V560G) and HMC 1.2 (KIT V560G/D816V); K562 comparator [4]
Low-nanomolar viability inhibition in the FLT3-ITD lines contrasted with little effect at 100 nM in the KIT-driven lines. This is model-dependent cellular selectivity, not proof of exclusive kinase specificity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series as plotted in Figure 2A; 100 nM KIT-line comparison.
- Exposure duration
- 48 h
- Method
- Cell viability in RPMI 1640 plus 10% FCS per Cell-Viability Assay methods; same-experiment triplicates.
- Co-treatment
- Crenolanib alone.
- Reported limits
- Exact salt and lot not specified. Figure 2A vehicle composition is not identified. No exact fitted IC50 is inferred from curves.
Methods and source locations
Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib
Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.
Figure 2A and caption; Results: Crenolanib Is approximately 100-Fold More Selective for FLT3 than KIT; Methods: Inhibitors and Cell-Viability Assay
Molm14 and MV4;11 viability: 48 h normalized cell viability; approximate value explicitly stated in Results, not fitted from the image. — Figure 2A; corresponding Results paragraph
HMC 1.1 and HMC 1.2 proliferation/viability: 48 h normalized viability; Figure 2A includes K562. Error bars: SD of triplicates from the same experiment. — Figure 2A and caption; corresponding Results paragraph
Suppression of PDGF-evoked ERK and Akt signaling
Cell-based study · Cultured healthy-control human dermal fibroblasts stimulated with PDGFAA or PDGFBB [2]
Crenolanib attenuated PDGFAA- and PDGFBB-induced ERK1/2 and Akt phosphorylation. Ligand-only, crenolanib-only and unstimulated conditions, total ERK/Akt and β-actin are shown. These downstream endpoints support PDGF-pathway inhibition without assigning a receptor-binding potency.
Literature-Reported Treatment Conditions
- Treatment concentration
- Crenolanib 100 nM; PDGFAA or PDGFBB 10 ng/mL.
- Exposure duration
- 1 h crenolanib pretreatment, followed by 30 min PDGF stimulation.
- Method
- Immunoblotting in healthy-control fibroblasts.
- Co-treatment
- Crenolanib with either PDGFAA or PDGFBB as agonist; ligand-only and basal controls.
- Reported limits
- Salt/form, lot and figure-specific vehicle are not established. Caption n = 3 per group is retained without assuming three independent donors.
Methods and source locations
Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib
Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.
Figure 2c and caption; Results: Crenolanib inhibits proliferation and migration of fibroblasts; Methods: Cell culture, Reagents, Immunoblotting
PDGF-induced ERK1/2 and Akt phosphorylation: Figure 2c: phospho- and total ERK1/2 and Akt, β-actin; relative values normalized to control, mean ± SD, n = 3 per group. No exact effect size transcribed. — Figure 2c and caption; corresponding Results paragraph